mitoxantrone has been researched along with Cardiotoxicity in 14 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
Cardiotoxicity: Damage to the HEART or its function secondary to exposure to toxic substances such as drugs used in CHEMOTHERAPY; IMMUNOTHERAPY; or RADIATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In this study, p-sulfonatocalix[6]arenes (SCA6) was proposed to construct a host-guest complexation to carry mitoxantrone (MIT) to maintain its anti-proliferation effect on HepG2 cells as well as to attenuate cardiotoxicity on H9C2 cells as a nano-size drug delivery system." | 8.12 | An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation. ( Jiang, M; Ren, X; Wang, H; Wang, M; Yu, X; Zhang, D; Zhu, Y, 2022) |
| "Mitoxantrone (MTX)- induced cardiotoxicity is a clinical concern that is limiting its use." | 8.02 | Subchronic administration of mitoxantrone and the influence of enzyme inhibitors on its induced cardiotoxicity in mice: role of NRF-2/CYP2E1. ( Alhaider, IA; Emeka, PM; Ibrahim, HIM; Mohamed, ME; Morsy, MA, 2021) |
| "Age is a known susceptibility factor for the cardiotoxicity of several anticancer drugs, including mitoxantrone (MTX)." | 7.81 | The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury. ( Bastos, Mde L; Carvalho, F; Costa, VM; Dores-Sousa, JL; Duarte, JA; Seabra, V, 2015) |
| "In this study, p-sulfonatocalix[6]arenes (SCA6) was proposed to construct a host-guest complexation to carry mitoxantrone (MIT) to maintain its anti-proliferation effect on HepG2 cells as well as to attenuate cardiotoxicity on H9C2 cells as a nano-size drug delivery system." | 4.12 | An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation. ( Jiang, M; Ren, X; Wang, H; Wang, M; Yu, X; Zhang, D; Zhu, Y, 2022) |
| "Mitoxantrone (MTX)- induced cardiotoxicity is a clinical concern that is limiting its use." | 4.02 | Subchronic administration of mitoxantrone and the influence of enzyme inhibitors on its induced cardiotoxicity in mice: role of NRF-2/CYP2E1. ( Alhaider, IA; Emeka, PM; Ibrahim, HIM; Mohamed, ME; Morsy, MA, 2021) |
| " Most pediatric oncology treatment groups assume that the hematologic toxicity of anthracycline agents is equivalent to their cardiotoxicity; for example, Children's Oncology Group substitution rules consider daunorubicin and epirubicin isoequivalent to doxorubicin, whereas mitoxantrone and idarubicin are considered 4 to 5 times as toxic as doxorubicin." | 3.91 | Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity. ( Armstrong, GT; Aune, GJ; Chow, EJ; Feijen, EAM; Green, DM; Hudson, MM; Kremer, LCM; Leisenring, WM; Loonen, J; Ness, KK; Oeffinger, KC; Robison, LL; Stratton, KL; van Dalen, EC; van der Pal, HJH; Yasui, Y, 2019) |
| "Mitoxantrone (MXT) is an androstenedione that is used to treat cancers and progressive forms of multiple sclerosis; however, its use is limited by its cardiotoxicity." | 3.85 | Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. ( Bradley, J; Burn, B; Chuang, G; Coy, DH; Maderdrut, JL; Subramaniam, V; Varner, KJ; Xia, H, 2017) |
| "Mitoxantrone (MTX) is an antineoplastic agent used to treat several types of cancers and on multiple sclerosis, which shows a high incidence of cardiotoxicity." | 3.85 | Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy. ( Bastos, ML; Carvalho, F; Carvalho, RA; Costa, VM; Gomes, AS; Pinto, M; Reis-Mendes, A; Remião, F; Sousa, E, 2017) |
| "Age is a known susceptibility factor for the cardiotoxicity of several anticancer drugs, including mitoxantrone (MTX)." | 3.81 | The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury. ( Bastos, Mde L; Carvalho, F; Costa, VM; Dores-Sousa, JL; Duarte, JA; Seabra, V, 2015) |
| "Cardiotoxicity is among the most important adverse effects of childhood cancer treatment." | 3.01 | Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review. ( Bolier, M; Feijen, EAM; Grotenhuis, HB; Hoesein, FAAM; Kouwenberg, TW; Kremer, LCM; Mavinkurve-Groothuis, AMC; Netea, SA; Slieker, MG; van Dalen, EC, 2023) |
| "Cardiotoxicity was ascertained through adverse event monitoring over the course of follow-up among 1,022 pediatric patients with acute myeloid leukemia treated in the Children's Oncology Group trial AAML0531." | 2.90 | Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group. ( Alonzo, T; Aplenc, R; Gamis, A; Gerbing, RB; Getz, KD; Ky, B; Leahy, AB; Leger, KJ; Sack, L; Sung, L; Woods, WG, 2019) |
| "Mitoxantrone (MTX) is an antineoplastic agent used to treat advanced breast cancer, prostate cancer, acute leukemia, lymphoma and multiple sclerosis." | 1.91 | Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells. ( Carvalho, F; Costa, VM; de Lourdes Bastos, M; Reis-Mendes, A; Remião, F; Sousa, E, 2023) |
| "Unfortunately, cardiotoxicity is a severe and common adverse effect in MTX-treated patients." | 1.56 | Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations. ( Almeida, MG; Capela, JP; Carvalho, F; Carvalho, RA; Costa, VM; Dores-Sousa, JL; Duarte, JA; Eleutério, RP; Lourdes Bastos, M; Remião, F; Rodrigues, PRS; Sousa, JR; Varner, KJ, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (57.14) | 24.3611 |
| 2020's | 6 (42.86) | 2.80 |
| Authors | Studies |
|---|---|
| Emeka, PM | 1 |
| Ibrahim, HIM | 1 |
| Alhaider, IA | 1 |
| Morsy, MA | 1 |
| Mohamed, ME | 1 |
| Yu, X | 1 |
| Wang, M | 1 |
| Wang, H | 1 |
| Ren, X | 1 |
| Jiang, M | 1 |
| Zhu, Y | 1 |
| Zhang, D | 1 |
| Reis-Mendes, A | 2 |
| Carvalho, F | 4 |
| Remião, F | 3 |
| Sousa, E | 2 |
| de Lourdes Bastos, M | 1 |
| Costa, VM | 4 |
| Kouwenberg, TW | 1 |
| van Dalen, EC | 2 |
| Feijen, EAM | 2 |
| Netea, SA | 1 |
| Bolier, M | 1 |
| Slieker, MG | 1 |
| Hoesein, FAAM | 1 |
| Kremer, LCM | 2 |
| Grotenhuis, HB | 1 |
| Mavinkurve-Groothuis, AMC | 1 |
| Atwal, M | 1 |
| Swan, RL | 1 |
| Rowe, C | 1 |
| Lee, KC | 1 |
| Lee, DC | 1 |
| Armstrong, L | 1 |
| Cowell, IG | 1 |
| Austin, CA | 1 |
| Capela, JP | 1 |
| Sousa, JR | 1 |
| Eleutério, RP | 1 |
| Rodrigues, PRS | 1 |
| Dores-Sousa, JL | 2 |
| Carvalho, RA | 2 |
| Lourdes Bastos, M | 1 |
| Duarte, JA | 2 |
| Almeida, MG | 1 |
| Varner, KJ | 2 |
| Yang, Z | 1 |
| Zhao, L | 1 |
| Wang, X | 1 |
| He, Z | 1 |
| Wang, Y | 1 |
| Subramaniam, V | 1 |
| Chuang, G | 1 |
| Xia, H | 1 |
| Burn, B | 1 |
| Bradley, J | 1 |
| Maderdrut, JL | 1 |
| Coy, DH | 1 |
| Damiani, RM | 2 |
| Moura, DJ | 2 |
| Viau, CM | 2 |
| Brito, V | 1 |
| Morás, AM | 1 |
| Henriques, JAP | 2 |
| Saffi, J | 2 |
| Getz, KD | 1 |
| Sung, L | 1 |
| Ky, B | 1 |
| Gerbing, RB | 1 |
| Leger, KJ | 1 |
| Leahy, AB | 1 |
| Sack, L | 1 |
| Woods, WG | 1 |
| Alonzo, T | 1 |
| Gamis, A | 1 |
| Aplenc, R | 1 |
| Leisenring, WM | 1 |
| Stratton, KL | 1 |
| Ness, KK | 1 |
| van der Pal, HJH | 1 |
| Armstrong, GT | 1 |
| Aune, GJ | 1 |
| Green, DM | 1 |
| Hudson, MM | 1 |
| Loonen, J | 1 |
| Oeffinger, KC | 1 |
| Robison, LL | 1 |
| Yasui, Y | 1 |
| Chow, EJ | 1 |
| Seabra, V | 1 |
| Bastos, Mde L | 1 |
| Caceres, RA | 1 |
| Gomes, AS | 1 |
| Pinto, M | 1 |
| Bastos, ML | 1 |
2 reviews available for mitoxantrone and Cardiotoxicity
| Article | Year |
|---|---|
Acute and early-onset cardiotoxicity in children and adolescents with cancer: a systematic review.
Topics: Adolescent; Anthracyclines; Cardiotoxicity; Child; Heart; Humans; Mitoxantrone; Neoplasms; Polyketid | 2023 |
Pathways of cardiac toxicity: comparison between chemotherapeutic drugs doxorubicin and mitoxantrone.
Topics: Animals; Antibiotics, Antineoplastic; Antigens, Neoplasm; Cardiotoxicity; DNA Topoisomerases, Type I | 2016 |
1 trial available for mitoxantrone and Cardiotoxicity
| Article | Year |
|---|---|
Occurrence of Treatment-Related Cardiotoxicity and Its Impact on Outcomes Among Children Treated in the AAML0531 Clinical Trial: A Report From the Children's Oncology Group.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cardiotoxicity; Child; Child, Preschool; Daunorubici | 2019 |
11 other studies available for mitoxantrone and Cardiotoxicity
| Article | Year |
|---|---|
Subchronic administration of mitoxantrone and the influence of enzyme inhibitors on its induced cardiotoxicity in mice: role of NRF-2/CYP2E1.
Topics: Animals; Antineoplastic Agents; Cardiotoxicity; Caspase 3; Cytochrome P-450 CYP2E1; Cytochrome P-450 | 2021 |
An application of p-sulfonatocalix[6]arenes to attenuate cardiotoxicity of mitoxantrone in vitro: preparation, characterization and evaluation.
Topics: Antineoplastic Agents; Apoptosis; Calixarenes; Calorimetry, Differential Scanning; Cardiotoxicity; C | 2022 |
Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells.
Topics: Antineoplastic Agents; Autophagy; Cardiotoxicity; Cytochrome P-450 Enzyme System; Humans; Male; Mito | 2023 |
Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations.
Topics: Anthracyclines; Cardiotoxicity; Cell Line, Tumor; Cell Survival; DNA Adducts; DNA Topoisomerases, Ty | 2019 |
Mitoxantrone impairs proteasome activity and prompts early energetic and proteomic changes in HL-1 cardiomyocytes at clinically relevant concentrations.
Topics: Animals; Apoptosis Regulatory Proteins; Cardiotoxicity; Cell Line; Dose-Response Relationship, Drug; | 2020 |
Ratiometric Delivery of Mitoxantrone and Berberine Co-encapsulated Liposomes to Improve Antitumor Efficiency and Decrease Cardiac Toxicity.
Topics: Animals; Antineoplastic Agents; Berberine; Cardiotoxicity; Cell Line, Tumor; Female; Heart; Humans; | 2021 |
Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice.
Topics: Animals; Cardiotoxicity; Cell Line, Tumor; Disease Models, Animal; Heart Injuries; Humans; Mice; Mit | 2017 |
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
Topics: Animals; Cardiotoxicity; Cell Line; Cell Survival; DNA Damage; Doxorubicin; Isoquinolines; Mitoxantr | 2018 |
Derivation of Anthracycline and Anthraquinone Equivalence Ratios to Doxorubicin for Late-Onset Cardiotoxicity.
Topics: Adolescent; Adult; Anthracyclines; Antibiotics, Antineoplastic; Cancer Survivors; Cardiotoxicity; Ch | 2019 |
The age factor for mitoxantrone's cardiotoxicity: multiple doses render the adult mouse heart more susceptible to injury.
Topics: Age Factors; Animals; Antineoplastic Agents; Aspartate Aminotransferases; Biomarkers; Body Weight; C | 2015 |
Naphthoquinoxaline metabolite of mitoxantrone is less cardiotoxic than the parent compound and it can be a more cardiosafe drug in anticancer therapy.
Topics: Adenine; Adenosine Triphosphate; Animals; Antineoplastic Agents; Autophagy; Cardiotoxicity; Cell Lin | 2017 |